TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tango Therapeutics Inc. (TNGX) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the company's lead program shows potential and analysts maintain optimistic price targets, the technical indicators, options sentiment, and financial performance suggest caution. The lack of significant positive trading signals and recent financial underperformance further reinforce a hold recommendation.
The MACD is negative and expanding (-0.155), indicating bearish momentum. RSI is at 26.728, which is neutral but leaning toward oversold territory. Moving averages are converging, showing no clear trend. Key support is at $11.303, and resistance is at $12.333. The stock is trading near its support level, suggesting limited immediate upside.
Analysts have reiterated buy ratings with price targets ranging from $14 to $19, citing the potential of the company's lead oncology program, vopimetostat, as a first-in-class therapy. Revenue growth in Q3 2025 was significant at 363.61% YoY.
Net income and EPS have significantly declined YoY (-154.46% and -148.15%, respectively). The MACD and RSI indicate bearish momentum. No recent news or congress trading data to act as a catalyst. The stock has a 30% chance of declining further in the short term.
In Q3 2025, revenue increased by 363.61% YoY to $53.81M, but net income dropped by -154.46% YoY to $15.88M, and EPS fell by -148.15% YoY to 0.13. Gross margin remained stable at 100%. While revenue growth is strong, profitability metrics have deteriorated significantly.
Analysts maintain a positive outlook with buy ratings and price targets between $14 and $19. They highlight the potential of vopimetostat in oncology and expect significant revenue growth by 2035. However, the stock's recent movement is seen as an overreaction to unrelated industry news.
